Literature DB >> 23299641

Do the frequencies of adverse events increase, decrease, or stay the same with long-term use of statins?

Karlyn Huddy1, Pavittarpaul Dhesi, Paul D Thompson.   

Abstract

Statins are widely used for their cholesterol-lowering properties and proven reduction of cardiovascular disease risk. Many patients take statins as long-term treatment for a variety of conditions without a clear-cut understanding of how treatment duration affects the frequency of adverse effects. We aimed to evaluate whether the frequencies of documented adverse events increase, decrease, or remain unchanged with long-term statin use. We reviewed the established literature to define the currently known adverse effects of statin therapy, including myopathy, central nervous system effects, and the appearance of diabetes, and the frequency of these events with long-term medication use. The frequency of adverse effects associated with long-term statin therapy appears to be low. Many patients who develop side effects from statin therapy do so relatively soon after initiation of therapy, so the frequency of side effects from statin therapy when expressed as a percentage of current users decreases over time. Nevertheless, patients may develop side effects such as muscle pain and weakness years after starting statin therapy; however, the absolute number of patients affected by statin myopathy increases with treatment duration. Also, clinical trials of statin therapy rarely exceed 5 years, so it is impossible to determine with certainty the frequency of long-term side effects with these drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23299641     DOI: 10.1007/s11883-012-0301-9

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  27 in total

1.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

2.  Statin-associated muscle-related adverse effects: a case series of 354 patients.

Authors:  Stephanie Cham; Marcella A Evans; Julie O Denenberg; Beatrice A Golomb
Journal:  Pharmacotherapy       Date:  2010-06       Impact factor: 4.705

3.  Long-term statin therapy is associated with better episodic memory in aged familial hypercholesterolemia patients in comparison with population controls.

Authors:  Laura Hyttinen; Annamari TuulioHenriksson; Alpo F Vuorio; Noora Kuosmanen; Tommi Härkänen; Seppo Koskinen; Timo E Strandberg
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

Review 5.  Statin safety: an overview and assessment of the data--2005.

Authors:  Harold Bays
Journal:  Am J Cardiol       Date:  2006-02-08       Impact factor: 2.778

6.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

7.  Statin-related adverse events: a meta-analysis.

Authors:  Matthew A Silva; Anna C Swanson; Pritesh J Gandhi; Gary R Tataronis
Journal:  Clin Ther       Date:  2006-01       Impact factor: 3.393

8.  The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment.

Authors:  Ihab Hajjar; Jeannie Schumpert; Victor Hirth; Darryl Wieland; G Paul Eleazer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-07       Impact factor: 6.053

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults.

Authors:  Joseph V Agostini; Mary E Tinetti; Ling Han; Gail McAvay; Joanne M Foody; John Concato
Journal:  J Am Geriatr Soc       Date:  2007-03       Impact factor: 5.562

View more
  7 in total

1.  Establishing the correlation between statins and cough: case series report and analysis of adverse drug reactions in the international databases.

Authors:  Carla Carnovale; Paolo Pellegrino; Valentina Perrone; Marta Gentili; Tatiana Brusadelli; Stefania Antoniazzi; Alessia Speziali; Cecilia Borsadoli; Marco Pozzi; Emilio Clementi; Sonia Radice
Journal:  Eur J Clin Pharmacol       Date:  2014-09-24       Impact factor: 2.953

2.  Statins Reduce the Risks of Relapse to Addiction in Rats.

Authors:  Claudia Chauvet; Celine Nicolas; Claire Lafay-Chebassier; Mohamed Jaber; Nathalie Thiriet; Marcello Solinas
Journal:  Neuropsychopharmacology       Date:  2015-10-15       Impact factor: 7.853

3.  Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway.

Authors:  Yong Wang; Chun Li; Qiyan Wang; Tianjiao Shi; Jing Wang; Hui Chen; Yan Wu; Jing Han; Shuzhen Guo; Yuanyuan Wang; Wei Wang
Journal:  BMC Complement Altern Med       Date:  2015-02-21       Impact factor: 3.659

4.  Improvement of hepatic bioavailability as a new step for the future of statin.

Authors:  Ivan M Petyaev
Journal:  Arch Med Sci       Date:  2015-04-23       Impact factor: 3.318

5.  Investigation of the Molecular Mechanisms Underlying the Antiatherogenic Actions of Kaempferol in Human THP-1 Macrophages.

Authors:  Etimad Huwait; Maha Ayoub; Sajjad Karim
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

6.  A Unique Combination of Nutritionally Active Ingredients Can Prevent Several Key Processes Associated with Atherosclerosis In Vitro.

Authors:  Joe W E Moss; Thomas S Davies; Iveta Garaiova; Sue F Plummer; Daryn R Michael; Dipak P Ramji
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240

Review 7.  Pleiotropic use of Statins as non-lipid-lowering drugs.

Authors:  Qijia Zhang; Jianlong Dong; Ze Yu
Journal:  Int J Biol Sci       Date:  2020-08-13       Impact factor: 6.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.